Evidence map›Paper›PMID 32926485›Full record

ArticleProtein science : a publication of the Protein Society2020

Roles of variable linker length in dual acting virucidal entry inhibitors on HIV-1 potency via on-the-fly free energy molecular simulations.

Steven T Gossert, Bibek Parajuli, Irwin Chaiken, Cameron F Abrams

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Steven T GossertDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-6123-3412
Bibek ParajuliDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Irwin ChaikenDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania, USA.
Cameron F AbramsDepartment of Chemical and Biological Engineering, Drexel University, Philadelphia, Pennsylvania, USA.
Drexel University · US

Funding

Dual-action virolytic entry inhibitors against HIV-1R01GM115249 · NIGMS · DREXEL UNIVERSITY · PI ABRAMS, CAMERON F, CHAIKEN, IRWIN M · 2015 to 2018
$2.0M
NIGMS NIH HHS R01 GM115249NIH HHS R01 GM115249
6 · The paper itself

Abstract

The Dual-Acting Virolytic Entry Inhibitors, or DAVEI's, are a class of recombinant chimera fusion proteins consisting of a lectin, a flexible polypeptide linker, and a fragment of the membrane-proximal external region (MPER) of HIV-1 gp41. DAVEIs trigger virolysis of HIV-1 virions through interactions with the trimeric envelope glycoprotein complex (Env), though the details of these interactions are not fully determined as yet. The purpose of this work was to use structural modeling to rationalize a dependence of DAVEI potency on the molecular length of the linker connecting the two components. We used temperature accelerated molecular dynamics and on-the-fly parameterization to compute free energy versus end-to-end distance for two different linker lengths, DAVEI L0 (His

Indexed as

Molecular Dynamics SimulationHIV-1HIV Envelope Protein gp41LectinsRecombinant Fusion ProteinsStructure-Activity Relationshipgp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp41LectinsRecombinant Fusion ProteinsHIV-1 envelope modelingHIV-1 envelope PMFmolecular dynamicson-the-fly parameterizationprotein free energy profilestemperature accelerated molecular dynamics

Identifiers

PMID32926485
PMCPMC7586904
OpenAlexW3084542621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.